This bill aims to eliminate the termination date for the prohibition against pharmacy benefit managers or health carriers requiring federally certified health entities to identify 340B drugs. To achieve this, the bill repeals specific sections from previous laws, namely Section 26 of Chapter 501 from 2021 and Section 1 of Chapter 259 from 2023.

Additionally, the bill establishes an immediate effective date upon passage and approval, ensuring that the changes take effect without delay. The repeal of these sections signifies a commitment to maintaining the current regulations surrounding 340B drugs and their identification by health entities.